Advanced Breast Cancer
Adding ribociclib to letrozole significantly prolonged progression-free survival compared with letrozole alone in postmenopausal women.
Short-term pre-operative treatment with palbociclib significantly reduced Ki67 in treatment-naïve patients with early-stage breast cancer.
Ado-trastuzumab emtansine in combination with docetaxel with or without pertuzumab appeared efficacious in breast cancer.
No association between early use of any supportive medications and end-of-life care among Medicare beneficiaries with advanced breast cancer.
Patients with early breast cancer experienced a pathologic complete response rate with nab-paclitaxel compared with paclitaxel.
An expert ASCO panel identified 9 biomarker tests that may help guide decisions on adjuvant systemic therapy for certain patients with breast cancer.
Abiraterone Acetate Plus Prednisone Beneficial for Some With AR-positive, Triple-negative Breast CancerFebruary 22, 2016
Treatment with abiraterone acetate plus prednisone was beneficial for some patients with molecular apocrine breast cancer.
The FDA approved palbociclib (Ibrance) in combination with fulvestrant for the treatment of patients with breast cancer.
Patients with metastatic cancer who continue to work may need the income or access to health insurance or simply have the desire to work, yet they face a number of hurdles.
The year 2015 brought treatment advances for patients with myriad cancer types, as reflected in U.S. Food and Drug administration approvals.
Dr Finn reviewed recent clinical study findings for palbociclib, a first-in-class CDK 4/6-specific inhibitor, abemaciclib, and ribociclib.
Declines in Top1-positive Circulating Tumor Cells Associated With Prolonged Survival After Etirinotecan PegolDecember 10, 2015
Declines in topoisomerase-I (Top1)-positive circulating tumor cells (CTCs) might be a biomarker of prolonged survival in advanced breast cancer.
A new sensitized blood test can help clinicians discover when breast cancers become resistant to standard hormone therapy.
Low-dose estradiol is an effective and well tolerated endocrine option in postmenopausal women with advanced breast cancer.
An exploratory analysis revealed that the efficacy of everolimus was independent of the most commonly altered genes in breast cancer.
For the first time in a decade, the American Cancer Society has updated its breast screening guidelines.
Etirinotecan pegol did not significantly improve overall survival in patients with heavily pre-treated advanced breast cancer.
Women in certain racial/ethnic groups are more likely to be diagnosed with more advanced breast cancer.
High tumor expression of ANXA1 could be predictive of trastuzumab resistance in patients with HER-2 positive breast cancer.
Women with mucinous or tubular/cribriform breast cancer had better outcomes than those with other histotypes.
Fulvestrant 500 mg may extend overall survival compared with anastrozole 1 mg as first-line endocrine therapy for advanced breast cancer.
FDA-approved immunotherapies are showing efficacy in different cancer types and combination therapies with new biologics are displaying increased efficacy.
Docetaxel/capecitabine regimen for breast cancer followed by capecitabine maintenance led to longer progression-free survival.
Weekly paclitaxel and every-3-week docetaxel regimens improved clinical outcomes in women with breast cancer.
Addition of everolimus notably prolonged progression-free survival in the HR-negative, HER2-positive breast cancer population.
No strong indication to favor either exemestane or tamoxifen for treatment of premenopausal women with early breast cancer.
Women exposed to the chemical in utero may be more likely to develop breast cancer.
Risk for breast cancer among obese women may be up to 58 percent higher than for normal-weight postmenopausal women.
Paclitaxel once per week remains the preferred palliative chemotherapy in patients with chemotherapy-naive advanced breast cancer.
Researchers have detected two new genetic markers of breast cancer survival.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy